Tagged with investment,

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

Puerto Rico GK CMO, a Puerto Rican contract manufacturing organization (CMO) recently inaugurated its manufacturing facility on the island. With the potential to manufacture advanced biologic and biosimilar products, the event could herald the beginning of a new era for Puerto Rican pharma manufacturing and was thus attended by two of the…

Sweden SwedenBIO gathers together actors from across the life science ecosystem of Sweden, with members ranging from small university spin-offs to large international companies, incubators, science parks, patent bureaus, and funding bodies. Jonas Ekstrand and Helena Strigård outline what makes Sweden such an innovation powerhouse, how SwedenBIO has fostered international connections,…

China Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high school chemistry teacher, and Zhong, a former factory technician, overtake Robin Li, founder of Chinese search engine giant Baidu, and…

Taiwan Rongjin Lin, chairman of Center Ventures and Center Laboratories shares his story of how he revived Center Laboratories from the brink of bankruptcy and repositioned the pharmaceutical company to become one of Taiwan’s leading biotechnology capital funds. Lin goes on to share his view on the Taiwanese biotech investment landscape,…

Puerto Rico Ivan Lugo, executive director at Puerto Rico’s Industry University Research Center, Inc. (INDUNIV) with over 40 years of global pharmaceutical expertise, explains how his not-for-profit organization promotes Puerto Rico’s competitiveness in science and technology by facilitating collaboration between industry, government and academia. He also highlights how the island aims to…

Puerto Rico With more than 50 years of experience in pharmaceutical manufacturing, Puerto Rico is today a manufacturing base for 11 of the world’s 20 largest pharmaceutical and biopharmaceutical companies. However, considering its economic struggles and rising competition both from US states and international manufacturing hubs such as Ireland and Singapore, the…

China The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the second largest biotech funding hub in the world.    Hansoh Pharmaceutical, one of China’s fastest-growing pharma companies, raised a billion…

Spain Jesús Donado, CEO of B. Braun Spain introduces the company’s strong footprint in Spain, as a manufacturing hub and a global centre of excellence for the company. Donado also discusses the challenge of offering solution and treatment-based services, while having to sell through product and volume-based tenders.   We are…

Sweden Swecare Foundation is a platform where academia, public sector actors, and the private sector come together to promote the internationalization and export growth of Swedish healthcare and life sciences. Anna Riby, regional director East Asia, Shampa Bari, regional director South Asia and Cécilia Wismar, office manager/CEO assistant, explain how the…

Opinion David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness month.   Alzheimer’s disease is a complex chronic disease characterized biologically by the accumulation of extracellular protein plaques, neurofibrillary protein tangles, a loss of functional synaptic connections, and eventually…

China On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business units, namely Innovative Medicines (including biosimilars and a new hospital business unit dealing with anti-infectives and sterile injectables), Consumer Healthcare,…